Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Caladrius Bio (CLBS)

Caladrius Bio (CLBS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,576
  • Shares Outstanding, K 10,400
  • Annual Sales, $ 0 K
  • Annual Income, $ -16,170 K
  • 60-Month Beta 1.59
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.20

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.54
  • Number of Estimates 1
  • High Estimate -0.54
  • Low Estimate -0.54
  • Prior Year -0.36
  • Growth Rate Est. (year over year) -50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.70 +17.78%
on 02/04/20
3.20 -0.62%
on 02/19/20
+0.07 (+2.25%)
since 01/17/20
3-Month
2.10 +51.43%
on 12/26/19
3.64 -12.64%
on 01/13/20
+0.39 (+13.98%)
since 11/19/19
52-Week
2.00 +59.00%
on 11/07/19
4.36 -27.06%
on 03/04/19
-1.02 (-24.29%)
since 02/19/19

Most Recent Stories

More News
The Keys to Successfully Timing the Markets - February 14, 2020

Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?

CLBS : 3.18 (+8.16%)
ABBV : 94.14 (+0.57%)
ADVM : 16.19 (-0.77%)
HNGR : 24.53 (+2.17%)
VBIV : 1.50 (-1.96%)
Caladrius Biosciences to Participate at Upcoming February Conferences

Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular...

CLBS : 3.18 (+8.16%)
The Market Timing Secrets No One Talks About - January 27, 2020

Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?

ABBV : 94.14 (+0.57%)
ADVM : 16.19 (-0.77%)
CLBS : 3.18 (+8.16%)
VBIV : 1.50 (-1.96%)
HNGR : 24.53 (+2.17%)
Caladrius Biosciences to Participate at Upcoming January Conferences

Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular...

CLBS : 3.18 (+8.16%)
Simple Market Timing Strategies That Work - January 07, 2020

In the long-run, does consistent market timing really matter to be a successful investor?

CLBS : 3.18 (+8.16%)
ABBV : 94.14 (+0.57%)
ADVM : 16.19 (-0.77%)
HNGR : 24.53 (+2.17%)
VBIV : 1.50 (-1.96%)
Caladrius Biosciences to Participate at Upcoming December Conferences

Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular...

CLBS : 3.18 (+8.16%)
Timing the Market, Is it Possible? - November 25, 2019

Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?

HNGR : 24.53 (+2.17%)
ABBV : 94.14 (+0.57%)
CLBS : 3.18 (+8.16%)
ADVM : 16.19 (-0.77%)
VBIV : 1.50 (-1.96%)
Critical Limb Ischemia Drug Market Size, Share 2019 Industry Trends, Growth Insight, Market Drivers Share, Competitive Analysis, Statistics, Regional, And Global Industry Forecast To 2025

Critical Limb Ischemia Drug Market 2019 Report offers a professional and in-depth study on the current state of the Global Critical Limb Ischemia Drug Market along with competitive landscape, Critical...

CLBS : 3.18 (+8.16%)
CYYNF : 0.7500 (+4.17%)
HEM.VN : 0.015 (+50.00%)
PSTI : 4.46 (-1.98%)
RNUGF : 1.8500 (-11.48%)
Caladrius Biosciences Reports Positive Results for CLBS16 from the ESCaPE-CMD Trial at American Heart Association Scientific Sessions 2019

Single administration of CLBS16 durably improves heart function and symptoms with no cell-related adverse events

CLBS : 3.18 (+8.16%)
Caladrius Biosciences Reports 2019 Third Quarter and Nine Month Financial Results and Provides Corporate Update

Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular...

CLBS : 3.18 (+8.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

See More Share

Trade CLBS with:

Business Summary

Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve...

See More

Key Turning Points

2nd Resistance Point 3.42
1st Resistance Point 3.18
Last Price 3.18
1st Support Level 2.72
2nd Support Level 2.50

See More

52-Week High 4.36
Fibonacci 61.8% 3.46
Fibonacci 50% 3.18
Last Price 3.18
Fibonacci 38.2% 2.90
52-Week Low 2.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar